Clinical Trials Browser

Recruiting × Carboplatin × Thoracic × Clear all

NCT05098132 2026-03-18

SYNERGY-101

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06151574 2026-03-18

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3 Recruiting

Lung Neoplasms

NCT06917079 2026-03-18

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT04267848 2026-03-17

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05198830 2026-03-17

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

Adenocarcinoma of Lung, Lung Neoplasms

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06712316 2026-03-17

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07063745 2026-03-17

MountainTAP-29

Phase 2/3 Recruiting

Lung Neoplasms

NCT07155174 2026-03-17

SEZanne

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT04165070 2026-03-16

MK-3475-01A

Phase 1/2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06538038 2026-03-16

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07190248 2026-03-16

KANDLELIT-007

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07287995 2026-03-16

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1/2 Recruiting

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT06305754 2026-03-13

MK-2870-009

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06312137 2026-03-13

TroFuse-019

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06422143 2026-03-13

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06875310 2026-03-13

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06119581 2026-03-12

SUNRAY-01

Phase 3 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06793215 2026-03-12

Krascendo 2

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07221474 2026-03-12

INTerpath-13

Phase 2 Recruiting

Squamous Non-small Cell Lung Cancer

NCT05061550 2026-03-11

NeoCOAST-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06623422 2026-03-11

INTerpath-009

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06788912 2026-03-10

MK-3475-01E

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06162221 2026-03-09

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07020221 2026-03-09

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04253964 2026-03-06

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05068232 2026-03-04

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06097728 2026-03-04

eVOLVE-Meso

Phase 3 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06646276 2026-03-04

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT05579366 2026-03-03

RAINFOL-01

Phase 1/2 Recruiting

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07100080 2026-03-03

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05797168 2026-03-02

FONTANA

Phase 1/2 Recruiting

GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT06417814 2026-03-02

TROPION-Lung15

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06452277 2026-03-02

SOHO-02

Phase 3 Recruiting

Advanced Non-small Cell Lung Cancer

NCT06772623 2026-02-27

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07005128 2026-02-27

DeLLphi-312

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT06447662 2026-02-25

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06692738 2026-02-25

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06946797 2026-02-24

CheckMate-1533

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06996782 2026-02-24

ALTAIR

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06236438 2026-02-23

LIVIGNO-4

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05789082 2026-02-20

KRAScendo 170

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07227597 2026-02-20

MK-6070-003

Phase 1/2 Recruiting

Small Cell Lung Cancer Extensive Stage

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Phase 2 Recruiting

Lung Neoplasms

NCT06333951 2026-02-19

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06731907 2026-02-18

MK-3475-01G

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06712355 2026-02-13

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06627647 2026-02-12

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Phase 3 Recruiting

Non-squamous Non-small Cell Lung Cancer